Evolution Biotechnologies announces publication of open-access paper on the selection of disease targets for phage therapy

Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced the publication of an invited paper written by Dr. David Harper, its Chief Executive Officer, as part of a special edition of the journal “Viruses”. The special edition is edited by Dr. Harald Brüssow and is focussed on “Hurdles for Phage Therapy (PT) to Become a Reality”. The paper, entitled “Criteria for Selecting Suitable Infectious Diseases for Phage Therapy” (Viruses 2018, 10(4), 177; https://doi.org/10.3390/v10040177) can be viewed at http://www.mdpi.com/1999-4915/10/4/177.

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on the outcomes of a successful feasibility study on biological control of the house dust mite. The company is also workong to develop further biological controls, including phage therapy for the antibiotic resistant superbug Pseudomonas aeruginosa. This will initially target disease in companion animals as a basis for the later development of human therapeutics.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com